SlideShare uma empresa Scribd logo
1 de 29
COPD-Asthma
Risk Factors for COPD

                    Nutrition

                    Infections

              Socio-economic
              status




Aging Populations
Percent Change in Age-Adjusted
            Death Rates, U.S., 1965-1998
Proportion of 1965 Rate
3.0
        Coronary          Stroke    Other CVD        COPD        All Other
2.5       Heart                                                   Causes
         Disease
2.0

1.5

1.0

0.5
          –59%            –64%        –35%           +163%          –7%
 0
      1965 - 1998    1965 - 1998   1965 - 1998    1965 - 1998   1965 - 1998
                                                 Source: NHLBI/NIH/DHHS
Prevalence of allergies and asthma in Pakistan
              M.Y. Noori, S.M. Hasnain, and M.A. Waqar.
          World Allergy Organization Journal & November 2007

• The frequency of wheezing was found to be 15.2%,
• while the diagnosed cases of asthma were 9.5%.
• The frequency of allergic rhinitis was found to be 34.3%.
• The frequency of those having allergic rhinitis as well as
  wheezing episodes was 8%.
• There was no statistically significant difference between
  asthmatics and non-asthmatics by sex (P-value:0.402).
• Socioeconomic status was found to affect significantly (p
  value 0.001) as the prevalence of diagnosed asthma cases
  was 6.17% in high socioeconomic class,13.11% in the
  middle-class and 2.4% in the low socioeconomic class.
• Family history of atopy was also found to be significantly
  higher in asthmatics.
NOCTURNAL ASTHMA IN SCHOOL CHILDREN OF SOUTH PUNJAB,PAKISTAN
              Ghulam Mustafa, Pervez Akber Khan, Imran Iqbal
                    J Ayub Med Coll Abbottabad 2008;20(3)



• The parents reported nocturnal asthma in 177
  (6%) of their children with an equal
  prevalence in boys and girls,
Anatomy
Pathogenesis of
            Cigarette smoke                 COPD
                Biomass particles
                   Particulates
                                                 Host factors
                                            Amplifying mechanisms



                            LUNG INFLAMMATION
Anti-oxidants
                                                      Anti-proteinases


      Oxidative
       stress                                   Proteinases

                                                     Repair
                                                   mechanisms

                         COPD PATHOLOGY
                                                 Source : Peter J. Barnes,
Differences in Inflammation and its Consequences: Asthma and COPD

                  ASTHMA                                       COPD
                  Allergens                                   Cigarette smoke

                                  Y Y
                              Y

       Ep cells          Mast cell                   Alv macrophage Ep cells




      CD4+ cell           Eosinophil                     CD8+ cell     Neutrophil
      (Th2)                                              (Tc1)
        Bronchoconstriction                        Small airway narrowing
               AHR                                 Alveolar destruction


                                    Airflow Limitation
Reversible                                                                Irreversible
                                                             Source : Peter J. Barnes,
COPD airway
Asthma airway
Changes in Large Airways of COPD Patients

   Mucus hypersecretion            Neutrophils in sputum



                                      Squamous metaplasia of epithelium
                                      No basement membrane thickening
Goblet cell
hyperplasia                            ↑ Macrophages

                                        ↑ CD8+ lymphocytes
         Mucus gland hyperplasia
                                          Little increase in
                                         airway smooth muscle




                                             Source : Peter J. Barnes,
                                             MD
Air Trapping in COPD
              Normal         Mild/moderate                 Severe
Inspiration                       COPD                     COPD
  small
  airway


    alveolar attachments      loss of elasticity   loss of alveolar attachments

Expiration


                                                                    closure




   ↓ Health                 Dyspnea                       Air trapping
    status             ↓ Exercise capacity               Hyperinflation
                                                         Source : Peter J. Barnes,
Changes in Small Airways in COPD Patients




                       Inflammatory exudate in lumen



                           Disrupted alveolar attachments



                       Thickened wall with inflammatory cells
                        - macrophages, CD8+ cells, fibroblasts

                        Peribronchial fibrosis
Lymphoid follicle



                                Source : Peter J. Barnes,
                                MD
Changes in the Lung Parenchyma in COPD
                Patients



                             Alveolar wall destruction




                                Loss of elasticity

                             Destruction of pulmonary
                             capillary bed

                       ↑ Inflammatory cells
                       macrophages, CD8+ lymphocytes

                             Source : Peter J. Barnes,
                             MD
Inflammatory Cells Involved in COPD
                                          Cigarette smoke
                                          (and other irritants)


            Epithelial                           Alveolar macrophage
              cells

                                         Chemotactic factors



                         CD8+
       Fibroblast lymphocyte

                                             Neutrophil           Monocyte
                                                           Neutrophil elastase
                                      PROTEASES Cathepsins
                                                           MMPs


         Fibrosis Alveolar wall destruction Mucus hypersecretion
       (Obstructive   (Emphysema)
       bronchiolitis)
                                                    Source : Peter J. Barnes, MD
Oxidative Stress in COPD
                                  Macrophage   Neutrophil




     Anti-proteases
      SLPI α 1-AT                                                  NF-κ B


      Proteolysis                                           IL-8       TNF-α
   ↓ HDAC2                   O2-, H202
                                                        Neutrophil
                             OH., ONOO-                 recruitment
↑Inflammation
   Steroid
  resistance


                         Isoprostanes     Plasma leak       Bronchoconstriction

     ↑ Mucus secretion
                                                        Source : Peter J. Barnes,
                                                        MD
Pulmonary Hypertension in
             COPD
     Chronic hypoxia


Pulmonary vasoconstriction
                                   Muscularization
 Pulmonary hypertension            Intimal
                                   hyperplasia
                                   Fibrosis
     Cor pulmonale                 Obliteration

                             Edema
          Death

                               Source : Peter J. Barnes, MD
Asthma
Emphysema- CT scan
Emphysema
Chronic bronchitis
PEF meters
Spirometry: Normal and
  Patients with COPD
Lung Volumes and Capacities
PFTs
           ASTHMA                       COPD
FEV1       Decreased in active asthma   Decreased-stage of disease
FVC        Decreased                    Decreased
FEV1/FVC   Decreased                    decreased
TLC        Normal or increased          Normal or increased
FRC        Normal or increased          Normal or increased
RV         Normal or Increased          Normal or increased
DLCO       Normal or Increased          Decreased in Emphysema
Therapy at Each Stage of COPD
     I: Mild             II: Moderate              III: Severe       IV: Very Severe



                                                                     FEV 1 /FVC < 70%

                                                FEV 1 /FVC < 70%    FEV 1 < 30%
                        FEV 1 /FVC < 70%                             predicted
 FEV 1 /FVC < 70%                              30% < FEV 1 <      or FEV 1 < 50%
                        50% < FEV 1 < 80%       50% predicted       predicted plus
 FEV 1 > 80%             predicted                                  chronic respiratory
Active reduction of risk factor(s); influenza vaccination
predicted                                                            failure
Add short-acting bronchodilator (when needed)
                       Add regular treatment with one or more long-acting
                       bronchodilators (when needed); Add rehabilitation
                                             Add inhaled glucocorticosteroids if
                                             repeated exacerbations
                                                                    Add long term
                                                                    oxygen if chronic
                                                                    respiratory failure.
                                                                    Consider surgical
                                                                    treatments

Mais conteúdo relacionado

Mais procurados

Pleural effusion 18022019
Pleural effusion 18022019Pleural effusion 18022019
Pleural effusion 18022019Itamar Tzadok
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolismparvathysree
 
Approach to patients with hemoptysis.pdf
Approach to patients with hemoptysis.pdfApproach to patients with hemoptysis.pdf
Approach to patients with hemoptysis.pdfamaliil
 
Pneumothoraxandpneumomediastinum 160830234614 (1)
Pneumothoraxandpneumomediastinum 160830234614 (1)Pneumothoraxandpneumomediastinum 160830234614 (1)
Pneumothoraxandpneumomediastinum 160830234614 (1)thanhvanyd
 
pneumothorax-141221114833-conversion-gate02.pdf
pneumothorax-141221114833-conversion-gate02.pdfpneumothorax-141221114833-conversion-gate02.pdf
pneumothorax-141221114833-conversion-gate02.pdfEmmanuelOluseyi1
 
Interstitial lung disease; Basic Understanding and approach
Interstitial lung disease; Basic Understanding and approachInterstitial lung disease; Basic Understanding and approach
Interstitial lung disease; Basic Understanding and approachDr Ravi Kumar Sharma
 
Cough investigations
Cough investigationsCough investigations
Cough investigationsAbino David
 
L9 10.lung consolidation CANCER AND PNEUMONIA
L9 10.lung consolidation CANCER AND PNEUMONIAL9 10.lung consolidation CANCER AND PNEUMONIA
L9 10.lung consolidation CANCER AND PNEUMONIAbilal natiq
 
physical examination in RESPIRATORY SYSTEM
physical examination in RESPIRATORY SYSTEMphysical examination in RESPIRATORY SYSTEM
physical examination in RESPIRATORY SYSTEMDrVenkatesan Ias
 
Network analysis in public health (2)
Network analysis in public health (2)Network analysis in public health (2)
Network analysis in public health (2)Jorge Pacheco
 
L 5.approach to dyspnea
L 5.approach to dyspneaL 5.approach to dyspnea
L 5.approach to dyspneabilal natiq
 

Mais procurados (20)

5 pneumonia
5 pneumonia5 pneumonia
5 pneumonia
 
Pleural effusion 18022019
Pleural effusion 18022019Pleural effusion 18022019
Pleural effusion 18022019
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolism
 
Hemoptysis
HemoptysisHemoptysis
Hemoptysis
 
Approach to patients with hemoptysis.pdf
Approach to patients with hemoptysis.pdfApproach to patients with hemoptysis.pdf
Approach to patients with hemoptysis.pdf
 
Pneumothoraxandpneumomediastinum 160830234614 (1)
Pneumothoraxandpneumomediastinum 160830234614 (1)Pneumothoraxandpneumomediastinum 160830234614 (1)
Pneumothoraxandpneumomediastinum 160830234614 (1)
 
pneumothorax-141221114833-conversion-gate02.pdf
pneumothorax-141221114833-conversion-gate02.pdfpneumothorax-141221114833-conversion-gate02.pdf
pneumothorax-141221114833-conversion-gate02.pdf
 
Pleural disease
Pleural diseasePleural disease
Pleural disease
 
Interstitial lung disease; Basic Understanding and approach
Interstitial lung disease; Basic Understanding and approachInterstitial lung disease; Basic Understanding and approach
Interstitial lung disease; Basic Understanding and approach
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Cough investigations
Cough investigationsCough investigations
Cough investigations
 
ARDS ppt
ARDS pptARDS ppt
ARDS ppt
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolism
 
L9 10.lung consolidation CANCER AND PNEUMONIA
L9 10.lung consolidation CANCER AND PNEUMONIAL9 10.lung consolidation CANCER AND PNEUMONIA
L9 10.lung consolidation CANCER AND PNEUMONIA
 
Bronchiectasis
BronchiectasisBronchiectasis
Bronchiectasis
 
Pulmonary edema
Pulmonary edemaPulmonary edema
Pulmonary edema
 
physical examination in RESPIRATORY SYSTEM
physical examination in RESPIRATORY SYSTEMphysical examination in RESPIRATORY SYSTEM
physical examination in RESPIRATORY SYSTEM
 
Network analysis in public health (2)
Network analysis in public health (2)Network analysis in public health (2)
Network analysis in public health (2)
 
L 5.approach to dyspnea
L 5.approach to dyspneaL 5.approach to dyspnea
L 5.approach to dyspnea
 
Copd
Copd Copd
Copd
 

Semelhante a Asthma copd

The 2009 COPD Malaysian Guidelines - What's Important From Emergency Medicine...
The 2009 COPD Malaysian Guidelines - What's Important From Emergency Medicine...The 2009 COPD Malaysian Guidelines - What's Important From Emergency Medicine...
The 2009 COPD Malaysian Guidelines - What's Important From Emergency Medicine...Chew Keng Sheng
 
COPD First Session
COPD First SessionCOPD First Session
COPD First SessionGamal Agmy
 
Non Communicable Diseases: COPD
Non Communicable Diseases: COPDNon Communicable Diseases: COPD
Non Communicable Diseases: COPDRalph Bawalan
 
Introduction to BioMAP<sup>®</sup> Systems
Introduction to BioMAP<sup>®</sup> SystemsIntroduction to BioMAP<sup>®</sup> Systems
Introduction to BioMAP<sup>®</sup> SystemsBioMAP® Systems
 
Apoptosis & it’s significance in oral diseases.pptx
Apoptosis & it’s significance in oral diseases.pptxApoptosis & it’s significance in oral diseases.pptx
Apoptosis & it’s significance in oral diseases.pptxDr Palak borade
 
How read chest xr 13
How  read  chest xr  13How  read  chest xr  13
How read chest xr 13ANAS ALSOHLE
 
09.17.08(c): Acute Respiratory Distress Syndrome
09.17.08(c): Acute Respiratory Distress Syndrome09.17.08(c): Acute Respiratory Distress Syndrome
09.17.08(c): Acute Respiratory Distress SyndromeOpen.Michigan
 
Inflammatory mediators in various molecular pathways involved in the developm...
Inflammatory mediators in various molecular pathways involved in the developm...Inflammatory mediators in various molecular pathways involved in the developm...
Inflammatory mediators in various molecular pathways involved in the developm...nisa aprilen
 
Interstitial Lung Disease
Interstitial Lung DiseaseInterstitial Lung Disease
Interstitial Lung Diseasedranimesharya
 

Semelhante a Asthma copd (20)

Ards ali
Ards aliArds ali
Ards ali
 
ild
ildild
ild
 
The 2009 COPD Malaysian Guidelines - What's Important From Emergency Medicine...
The 2009 COPD Malaysian Guidelines - What's Important From Emergency Medicine...The 2009 COPD Malaysian Guidelines - What's Important From Emergency Medicine...
The 2009 COPD Malaysian Guidelines - What's Important From Emergency Medicine...
 
COPD First Session
COPD First SessionCOPD First Session
COPD First Session
 
Non Communicable Diseases: COPD
Non Communicable Diseases: COPDNon Communicable Diseases: COPD
Non Communicable Diseases: COPD
 
Asthma versus COPD
Asthma versus COPDAsthma versus COPD
Asthma versus COPD
 
Acute lung injury
Acute lung injuryAcute lung injury
Acute lung injury
 
COPD back to basis
COPD back to basisCOPD back to basis
COPD back to basis
 
Introduction to BioMAP<sup>®</sup> Systems
Introduction to BioMAP<sup>®</sup> SystemsIntroduction to BioMAP<sup>®</sup> Systems
Introduction to BioMAP<sup>®</sup> Systems
 
Update on vasculitis
Update on vasculitisUpdate on vasculitis
Update on vasculitis
 
Apoptosis & it’s significance in oral diseases.pptx
Apoptosis & it’s significance in oral diseases.pptxApoptosis & it’s significance in oral diseases.pptx
Apoptosis & it’s significance in oral diseases.pptx
 
How read chest xr 13
How  read  chest xr  13How  read  chest xr  13
How read chest xr 13
 
Apoptosis seminar f
Apoptosis seminar fApoptosis seminar f
Apoptosis seminar f
 
Mac mahon venice ild pdf f
Mac mahon venice  ild pdf fMac mahon venice  ild pdf f
Mac mahon venice ild pdf f
 
09.17.08(c): Acute Respiratory Distress Syndrome
09.17.08(c): Acute Respiratory Distress Syndrome09.17.08(c): Acute Respiratory Distress Syndrome
09.17.08(c): Acute Respiratory Distress Syndrome
 
Dr hardik patel
Dr hardik patelDr hardik patel
Dr hardik patel
 
Inflammatory mediators in various molecular pathways involved in the developm...
Inflammatory mediators in various molecular pathways involved in the developm...Inflammatory mediators in various molecular pathways involved in the developm...
Inflammatory mediators in various molecular pathways involved in the developm...
 
Copd and asthma
Copd and asthmaCopd and asthma
Copd and asthma
 
Meningitis
MeningitisMeningitis
Meningitis
 
Interstitial Lung Disease
Interstitial Lung DiseaseInterstitial Lung Disease
Interstitial Lung Disease
 

Mais de Muhammad Saim

Kub guide without tos
Kub guide without tosKub guide without tos
Kub guide without tosMuhammad Saim
 
Chronic stable angina
Chronic stable anginaChronic stable angina
Chronic stable anginaMuhammad Saim
 
Clinical cases for ccf
Clinical cases for ccfClinical cases for ccf
Clinical cases for ccfMuhammad Saim
 
Dr fahad anti arrythmic drugs
Dr fahad anti arrythmic drugsDr fahad anti arrythmic drugs
Dr fahad anti arrythmic drugsMuhammad Saim
 
Clinical cases for ccf
Clinical cases for ccfClinical cases for ccf
Clinical cases for ccfMuhammad Saim
 
2003 cvs shifa permeation through biological membranes
2003 cvs shifa permeation through biological membranes2003 cvs shifa permeation through biological membranes
2003 cvs shifa permeation through biological membranesMuhammad Saim
 
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011Muhammad Saim
 
Retina and visual tract
Retina and visual tractRetina and visual tract
Retina and visual tractMuhammad Saim
 
Cranial nerves iii, iv,vi
Cranial nerves iii, iv,viCranial nerves iii, iv,vi
Cranial nerves iii, iv,viMuhammad Saim
 

Mais de Muhammad Saim (20)

Mc
McMc
Mc
 
Kub guide without tos
Kub guide without tosKub guide without tos
Kub guide without tos
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Chronic stable angina
Chronic stable anginaChronic stable angina
Chronic stable angina
 
Clinical cases for ccf
Clinical cases for ccfClinical cases for ccf
Clinical cases for ccf
 
Dr fahad anti arrythmic drugs
Dr fahad anti arrythmic drugsDr fahad anti arrythmic drugs
Dr fahad anti arrythmic drugs
 
Hypertension
HypertensionHypertension
Hypertension
 
Clinical cases for ccf
Clinical cases for ccfClinical cases for ccf
Clinical cases for ccf
 
2003 cvs shifa permeation through biological membranes
2003 cvs shifa permeation through biological membranes2003 cvs shifa permeation through biological membranes
2003 cvs shifa permeation through biological membranes
 
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
 
Arrythmia
ArrythmiaArrythmia
Arrythmia
 
Cvs
CvsCvs
Cvs
 
Retina and visual tract
Retina and visual tractRetina and visual tract
Retina and visual tract
 
Orbit
OrbitOrbit
Orbit
 
Lids,lacrimation
Lids,lacrimationLids,lacrimation
Lids,lacrimation
 
Cranial nerves iii, iv,vi
Cranial nerves iii, iv,viCranial nerves iii, iv,vi
Cranial nerves iii, iv,vi
 
Eye layers 1
Eye layers 1Eye layers 1
Eye layers 1
 
Refractive errors
Refractive errorsRefractive errors
Refractive errors
 
Limbic system
Limbic systemLimbic system
Limbic system
 

Asthma copd

  • 2.
  • 3. Risk Factors for COPD Nutrition Infections Socio-economic status Aging Populations
  • 4.
  • 5. Percent Change in Age-Adjusted Death Rates, U.S., 1965-1998 Proportion of 1965 Rate 3.0 Coronary Stroke Other CVD COPD All Other 2.5 Heart Causes Disease 2.0 1.5 1.0 0.5 –59% –64% –35% +163% –7% 0 1965 - 1998 1965 - 1998 1965 - 1998 1965 - 1998 1965 - 1998 Source: NHLBI/NIH/DHHS
  • 6. Prevalence of allergies and asthma in Pakistan M.Y. Noori, S.M. Hasnain, and M.A. Waqar. World Allergy Organization Journal & November 2007 • The frequency of wheezing was found to be 15.2%, • while the diagnosed cases of asthma were 9.5%. • The frequency of allergic rhinitis was found to be 34.3%. • The frequency of those having allergic rhinitis as well as wheezing episodes was 8%. • There was no statistically significant difference between asthmatics and non-asthmatics by sex (P-value:0.402). • Socioeconomic status was found to affect significantly (p value 0.001) as the prevalence of diagnosed asthma cases was 6.17% in high socioeconomic class,13.11% in the middle-class and 2.4% in the low socioeconomic class. • Family history of atopy was also found to be significantly higher in asthmatics.
  • 7. NOCTURNAL ASTHMA IN SCHOOL CHILDREN OF SOUTH PUNJAB,PAKISTAN Ghulam Mustafa, Pervez Akber Khan, Imran Iqbal J Ayub Med Coll Abbottabad 2008;20(3) • The parents reported nocturnal asthma in 177 (6%) of their children with an equal prevalence in boys and girls,
  • 9. Pathogenesis of Cigarette smoke COPD Biomass particles Particulates Host factors Amplifying mechanisms LUNG INFLAMMATION Anti-oxidants Anti-proteinases Oxidative stress Proteinases Repair mechanisms COPD PATHOLOGY Source : Peter J. Barnes,
  • 10. Differences in Inflammation and its Consequences: Asthma and COPD ASTHMA COPD Allergens Cigarette smoke Y Y Y Ep cells Mast cell Alv macrophage Ep cells CD4+ cell Eosinophil CD8+ cell Neutrophil (Th2) (Tc1) Bronchoconstriction Small airway narrowing AHR Alveolar destruction Airflow Limitation Reversible Irreversible Source : Peter J. Barnes,
  • 13. Changes in Large Airways of COPD Patients Mucus hypersecretion Neutrophils in sputum Squamous metaplasia of epithelium No basement membrane thickening Goblet cell hyperplasia ↑ Macrophages ↑ CD8+ lymphocytes Mucus gland hyperplasia Little increase in airway smooth muscle Source : Peter J. Barnes, MD
  • 14. Air Trapping in COPD Normal Mild/moderate Severe Inspiration COPD COPD small airway alveolar attachments loss of elasticity loss of alveolar attachments Expiration closure ↓ Health Dyspnea Air trapping status ↓ Exercise capacity Hyperinflation Source : Peter J. Barnes,
  • 15. Changes in Small Airways in COPD Patients Inflammatory exudate in lumen Disrupted alveolar attachments Thickened wall with inflammatory cells - macrophages, CD8+ cells, fibroblasts Peribronchial fibrosis Lymphoid follicle Source : Peter J. Barnes, MD
  • 16. Changes in the Lung Parenchyma in COPD Patients Alveolar wall destruction Loss of elasticity Destruction of pulmonary capillary bed ↑ Inflammatory cells macrophages, CD8+ lymphocytes Source : Peter J. Barnes, MD
  • 17. Inflammatory Cells Involved in COPD Cigarette smoke (and other irritants) Epithelial Alveolar macrophage cells Chemotactic factors CD8+ Fibroblast lymphocyte Neutrophil Monocyte Neutrophil elastase PROTEASES Cathepsins MMPs Fibrosis Alveolar wall destruction Mucus hypersecretion (Obstructive (Emphysema) bronchiolitis) Source : Peter J. Barnes, MD
  • 18. Oxidative Stress in COPD Macrophage Neutrophil Anti-proteases SLPI α 1-AT NF-κ B Proteolysis IL-8 TNF-α ↓ HDAC2 O2-, H202 Neutrophil OH., ONOO- recruitment ↑Inflammation Steroid resistance Isoprostanes Plasma leak Bronchoconstriction ↑ Mucus secretion Source : Peter J. Barnes, MD
  • 19. Pulmonary Hypertension in COPD Chronic hypoxia Pulmonary vasoconstriction Muscularization Pulmonary hypertension Intimal hyperplasia Fibrosis Cor pulmonale Obliteration Edema Death Source : Peter J. Barnes, MD
  • 25. Spirometry: Normal and Patients with COPD
  • 26.
  • 27. Lung Volumes and Capacities
  • 28. PFTs ASTHMA COPD FEV1 Decreased in active asthma Decreased-stage of disease FVC Decreased Decreased FEV1/FVC Decreased decreased TLC Normal or increased Normal or increased FRC Normal or increased Normal or increased RV Normal or Increased Normal or increased DLCO Normal or Increased Decreased in Emphysema
  • 29. Therapy at Each Stage of COPD I: Mild II: Moderate III: Severe IV: Very Severe  FEV 1 /FVC < 70%  FEV 1 /FVC < 70%  FEV 1 < 30%  FEV 1 /FVC < 70% predicted  FEV 1 /FVC < 70%  30% < FEV 1 < or FEV 1 < 50%  50% < FEV 1 < 80% 50% predicted predicted plus  FEV 1 > 80% predicted chronic respiratory Active reduction of risk factor(s); influenza vaccination predicted failure Add short-acting bronchodilator (when needed) Add regular treatment with one or more long-acting bronchodilators (when needed); Add rehabilitation Add inhaled glucocorticosteroids if repeated exacerbations Add long term oxygen if chronic respiratory failure. Consider surgical treatments

Notas do Editor

  1. Pathogenesis of COPD, illustrating the central role of inflammation
  2. Changes in large airways of COPD patients. The epithelium often shows squamous metaplasia and there is goblet cell and submucosal gland hyperplasia, resulting in mucus hypersecretion. The airway wall is infiltrated with macrophages and CD8+ lymphocytes, whereas neutrophils predominate in the airway lumen and around submucosal glands. Airway smooth muscle and basement membrane are minimally increased compared to the findings in asthma.
  3. Air trapping in COPD. During expiration small airways narrow but closure is prevented by the elasticity of alveolar attachments. In COPD patients there is a loss of elasticity with greater narrowing in small airways, which may close completely when there is loss of alveolar attachments as a result of emphysema. This results in air trapping and hyperinflation, leading to dyspnea and reduced exercise capacity.
  4. Changes in small airways in COPD patients. The airway wall is thickened and infiltrated with inflammatory cells, predominately macrophages and CD8+ lymphocytes, with increased numbers of fibroblasts. In severe COPD there are also lymphoid follicles. The lumen is often filled with an inflammatory exudate and mucus. There is peribronchial fibrosis and airway smooth muscle may be increased, resulting in narrowing of the airway.
  5. Changes in the lung parenchyma in COPD patients. There is loss of elasticity and alveolar wall destruction, and accumulation of inflammatory cells, predominantly macrophages and CD8+ lymphocytes. The destructive changes reduce the pulmonary capillary bed. The left panel shows a scanning electron micrograph of a patient with emphysema demonstrating the enlargement of alveoli and destruction of the alveolar walls.
  6. Inflammatory cells involved in COPD. Cigarette smoke activates macrophages and epithelial cells to release chemotactic factors that recruit neutrophils, monocytes and CD8+ T-lymphocytes from the circulation. They also release factors that activate fibroblasts leading to small airway obstruction (obstructive bronchiolitis). Proteases released from neutrophils and macrophages may cause mucus hypersecretion and emphysema.
  7. Oxidative stress in COPD has several detrimental consequences, including activation of the transcription factor nuclear factor-κB (NF-κB), reduction in antiproteases, plasma leakage and mucus hypersecretion. In addition it reduces histone deacetylase-2, resulting in amplified inflammation and reduced anti-inflammatory response to corticosteroids.
  8. This provides a summary of the recommended treatment at each stage of COPD.